BTK and B-cell chronic lymphocytic leukemia: As observed by Cervantes-Gomez et al., ibrutinib therapy determined a decrease in phospho- as well as total BTK protein in CLL lymphocytes and a decline in BTK total protein was observed also in circulating leukemic cells after 4 weeks of treatment (38, 39).